Effect of milnacipran on pain in patients with rheumatoid arthritis with widespread pain: A randomized blinded crossover trial

Journal of Rheumatology

Volumn 43, Issue 1, 2016, Pages 38-45

  Lee, Yvonne C ^a   Massarotti, Elena ^a   Edwards, Robert R ^a   Lu, Bing ^a   Liu, ChihChin ^a   Lo, Yuanyu ^a   Wohlfahrt, Alyssa ^a   Kim, Nancy D ^b   Clauw, Daniel J ^c   Solomon, Daniel H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Analgesia; Pain; Rheumatoid arthritis

Indexed keywords

MILNACIPRAN; PLACEBO; CYCLOPROPANE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ANXIETY DISORDER; ARTICLE; BRIEF PAIN INVENTORY; CLINICAL ARTICLE; COLITIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ACTIVITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART PALPITATION; HUMAN; JOINT SWELLING; LOSS OF APPETITE; MALE; NAUSEA; NOCICEPTION; PAIN; PAIN INTENSITY; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SELF REPORT; TREATMENT DURATION; TREATMENT OUTCOME; WIDESPREAD PAIN; AGED; ANALGESIA; ARTHRITIS, RHEUMATOID; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; FOLLOW UP; MIDDLE AGED; PAIN MEASUREMENT; PAIN THRESHOLD; PATHOPHYSIOLOGY; PROCEDURES; REFERENCE VALUE; SEVERITY OF ILLNESS INDEX; UNITED STATES; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; ADULT; AGED; ARTHRITIS, RHEUMATOID; CONFIDENCE INTERVALS; CROSS-OVER STUDIES; CYCLOPROPANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PAIN MANAGEMENT; PAIN MEASUREMENT; PAIN THRESHOLD; REFERENCE VALUES; SELF REPORT; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED STATES;

EID: 85011932079     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.150550     Document Type: Article

References (50)

1. American College of Rheumatology Pain Management Task Force. Report of the American College of Rheumatology Pain Management Task Force. Arthritis Care Res 2010;62:590-9.
2. McWilliams DF, Zhang W, Mansell JS, Kiely PD, Young A, Walsh DA. Predictors of change in bodily pain in early rheumatoid arthritis: an inception cohort study. Arthritis Care Res 2012;64:1505-13.
3. Andersson ML, Svensson B, Bergman S. Chronic widespread pain in patients with rheumatoid arthritis and the relation between pain and disease activity measures over the first 5 years. J Rheumatol 2013;40:1977-85.
4. Meeus M, Vervisch S, De Clerck LS, Moorkens G, Hans G, Nijs J. Central sensitization in patients with rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum 2012;41:556-67.
5. Pollard LC, Kingsley GH, Choy EH, Scott DL. Fibromyalgic rheumatoid arthritis and disease assessment. Rheumatology 2010;49:924-8.
6. Goldenberg DL, Clauw DJ, Fitzcharles MA. New concepts in pain research and pain management of the rheumatic diseases. Semin Arthritis Rheum 2011;41:319-34.
7. Barsky AJ, Ahern DK, Orav EJ, Nestoriuc Y, Liang MH, Berman IT, et al. A randomized trial of three psychosocial treatments for the symptoms of rheumatoid arthritis. Semin Arthritis Rheum 2010;40:222-32.
8. Lee YC, Lu B, Boire G, Haraoui BP, Hitchon CA, Pope JE, et al. Incidence and predictors of secondary fibromyalgia in an early arthritis cohort. Ann Rheum Dis 2013;72:949-54.
9. Lee YC, Chibnik LB, Lu B, Wasan AD, Edwards RR, Fossel AH, et al. The relationship between disease activity, sleep, psychiatric distress and pain sensitivity in rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther 2009;11:R160.
10. Arendt-Nielsen L, Eskehave TN, Egsgaard LL, Petersen KK, Graven-Nielsen T, Hoeck HC, et al. Association between experimental pain biomarkers and serologic markers in patients with different degrees of painful knee osteoarthritis. Arthritis Rheumatol 2014;66:3317-26.
11. Lluch E, Torres R, Nijs J, Van Oosterwijck J. Evidence for central sensitization in patients with osteoarthritis pain: a systematic literature review. E J Pain 2014;18:1367-75.
12. Graven-Nielsen T, Wodehouse T, Langford RM, Arendt-Nielsen L, Kidd BL. Normalization of widespread hyperesthesia and facilitated spatial summation of deep-tissue pain in knee osteoarthritis patients after knee replacement. Arthritis Rheum 2012;64:2907-16.
13. Richards BL, Whittle SL, Buchbinder R. Antidepressants for pain management in rheumatoid arthritis. Cochrane Database Syst Rev 2011:CD008920.
14. Richards BL, Whittle SL, van der Heijde DM, Buchbinder R. The efficacy and safety of antidepressants in inflammatory arthritis: a Cochrane systematic review. J Rheumatol Suppl. 2012 Sep;90:21-7.
15. Sarzi Puttini P, Cazzola M, Boccassini L, Ciniselli G, Santandrea S, Caruso I, et al. A comparison of dothiepin versus placebo in the treatment of pain in rheumatoid arthritis and the association of pain with depression. J Int Med Res 1988;16:331-7.
16. Choy E, Marshall D, Gabriel ZL, Mitchell SA, Gylee E, Dakin HA. A systematic review and mixed treatment comparison of the efficacy of pharmacological treatments for fibromyalgia. Semin Arthritis Rheum 2011;41:335-45.e6.
17. Bradley LA, Wohlreich MM, Wang F, Gaynor PJ, Robinson MJ, D'Souza DN, et al. Pain response profile of patients with fibromyalgia treated with duloxetine. Clin J Pain 2010;26:498-504.
18. Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004;50:2974-84.
19. Carville SF, Arendt-Nielsen L, Bliddal H, Blotman F, Branco JC, Buskila D, et al; EULAR. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008;67:536-41.
20. Ormseth MJ, Eyler AE, Hammonds CL, Boomershine CS. Milnacipran for the management of fibromyalgia syndrome. J Pain Res 2010;3:15-24.
21. Mease PJ, Clauw DJ, Gendreau RM, Rao SG, Kranzler J, Chen W, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial. J Rheumatol 2009;36:398-409.
22. Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 2008;30:1988-2004.
23. Harden RN, Bruehl S. Conducting clinical trials to establish drug efficacy in chronic pain. Am J Phys Med Rehab 2001;80:547-57.
24. Richens A. Proof of efficacy trials: cross-over versus parallel-group. Epilepsy Res 2001;45:43-7.
25. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23:129-38.
26. Wolfe F. Pain extent and diagnosis: development and validation of the regional pain scale in 12,799 patients with rheumatic disease. J Rheumatol 2003;30:369-78.
27. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
28. Wolfe F, Rasker JJ. The Symptom Intensity Scale, fibromyalgia, and the meaning of fibromyalgia-like symptoms. J Rheumatol 2006;33:2291-9.
29. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 2002;52:69-77.
30. Hays RD, Stewart AL. Sleep measures. In: Stewart AL, Ware JE Jr, eds. Measuring functioning and well-being: the medical outcomes study approach. Durham: Durham University Press; 1992:235-59.
31. Sullivan MJL, Bishop SR, Pivik J. The Pain Catastrophizing Scale: development and validation. Psychol Assess 1995;7:524-32.
32. Lee YC, Lu B, Edwards RR, Wasan AD, Nassikas NJ, Clauw DJ, et al. The role of sleep problems in central pain processing in rheumatoid arthritis. Arthritis Rheum 2013;65:59-68.
33. Petzke F, Khine A, Williams D, Groner K, Clauw DJ, Gracely RH. Dolorimetry performed at 3 paired tender points highly predicts overall tenderness. J Rheumatol 2001;28:2568-9.
34. Biurrun Manresa JA, Fritsche R, Vuilleumier PH, Oehler C, Mørch CD, Arendt-Nielsen L, et al. Is the conditioned pain modulation paradigm reliable? A test-retest assessment using the nociceptive withdrawal reflex. PLoS One 2014;9:e100241.
35. Lewis GN, Heales L, Rice DA, Rome K, McNair PJ. Reliability of the conditioned pain modulation paradigm to assess endogenous inhibitory pain pathways. Pain Res Manag 2012;17:98-102.
36. Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL. Defining the clinically important difference in pain outcome measures. Pain 2000;88:287-94.
37. Sarzi-Puttini P, Salaffi F, Di Franco M, Bazzichi L, Cassisi G, Casale R, et al. Pain in rheumatoid arthritis: a critical review. Reumatismo 2014;66:18-27.
38. Walsh DA, McWilliams DF. Pain in rheumatoid arthritis. Curr Pain Headache Rep 2012;16:509-17.
39. Gendreau RM, Thorn MD, Gendreau JF, Kranzler JD, Ribeiro S, Gracely RH, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 2005;32:1975-85.
40. Vitton O, Gendreau M, Gendreau J, Kranzler J, Rao SG. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol 2004;19 Suppl 1:S27-35.
41. Geisser ME, Palmer RH, Gendreau RM, Wang Y, Clauw DJ. A pooled analysis of two randomized, double-blind, placebo-controlled trials of milnacipran monotherapy in the treatment of fibromyalgia. Pain Pract 2011;11:120-31.
42. Uçeyler N, Häuser W, Sommer C. A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome. Arthritis Rheum 2008;59:1279-98.
43. Goldenberg DL, Clauw DJ, Palmer RH, Mease P, Chen W, Gendreau RM. Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study. Pain Med 2010;11:180-94.
44. Arnold LM, Gendreau RM, Palmer RH, Gendreau JF, Wang Y. Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:2745-56.
45. Branco JC, Zachrisson O, Perrot S, Mainguy Y; Multinational Coordinator Study Group. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. J Rheumatol 2010;37:851-9.
46. Häuser W, Urrútia G, Tort S, Uçeyler N, Walitt B. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database Syst Rev 2013;1:CD010292.
47. Arnold LM, Palmer RH, Ma Y. A 3-year, open-label, flexible-dosing study of milnacipran for the treatment of fibromyalgia. Clin J Pain 2013;29:1021-8.
48. Puozzo C, Panconi E, Deprez D. Pharmacology and pharmacokinetics of milnacipran. Int Clin Psychopharmacol 2002;17 Suppl 1:S25-35.
49. Kyle JA, Dugan BD, Testerman KK. Milnacipran for treatment of fibromyalgia. Ann Pharmacother 2010;44:1422-9.
50. Chow SC, Liu JP. Design and analysis of bioavailability and bioequivalence studies, 3rd edition. Boca Raton: Chapman and Hall/CRC; 2000.